Adam Torres and Kenneth L. Londoner discussed BioSig and the treatment of cardiovascular arrhythmias.
Subscribe: iTunes / Spotify / Stitcher / RSS
Apply to be a guest on our podcast here
BioSig Technologies is an advanced digital signal processing technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. In this episode, Adam Torres interviewed Kenneth L. Londoner, Founder & CEO at BioSig Tech. Explore BioSig at the Milken Conference 2023.
Watch Full Interview:
About Kenneth L. Londoner
Kenneth L Londoner is the founder, CEO, chairman, and director of BioSig Technologies, Inc. He founded the company back in February 2009. Mr. Londoner is also the Managing Partner of Endicott Management Partners, LLC, a firm dedicated to assisting emerging growth companies in their corporate development and investing needs since 2004.
From April 2007 to October 2009, Mr. Londoner was the executive vice president of NewCardio, Inc., a silicon valley based cardiac software company. From May 2012 to March 2014 Kenneth L Londoner also served as a Director of the turnaround at Alliqua BioMedical, Inc.
Londoner is a co-founder of Safe Ports Holdings, LLC, in Charleston, South Carolina, a port security and logistics company. The company was founded in 2005, and the main business was building and selling inland port development projects to Dubai Ports World. Mr. Londoner is a member of the Safe Ports Board of Directors.
About BioSig Tech
BioSig is a digital signal processing company that unites expertise in medical engineering, intellectual property, and workflow to deliver superior intracardiac signals with unprecedented precision.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™ is a surface electrocardiogram (ECG) and analysis system that is designed to help identify appropriate areas of tissues that create a heart rhythm disturbance (arrhythmia).
BioSig’s passion for helping others goes beyond its technology platform. In 2015, BioSig introduced its internship program, aimed at providing students with a meaningful and impactful experience. The BioSig Internship program is looking for qualified students that will become key contributors to its dynamic team. As a BioSig intern, you will directly observe the critical intersection between science and business, all of which will enable you to better plan for your future careers and/or postgraduate studies.
About Milken Institute
The Milken Institute is a nonprofit, nonpartisan think tank focused on accelerating measurable progress on the path to a meaningful life. With a focus on financial, physical, mental, and environmental health, we bring together the best ideas and innovative resourcing to develop blueprints for tackling some of our most critical global issues through the lens of what’s pressing now and what’s coming next.
Full Unedited Transcript
Hey, I’d like to welcome you to another episode of Mission Matters. My name is Adam Torres and I’m proud to announce and happy and excited that we are at the Milkin Conference 2023. And today my guest is Kenneth Londoner, who is the founder over at Bio Tech. Ken, welcome to the show. Thank you for having me.
Nice to be here. All right, Ken. So, uh, I’m excited to learn more about Bio Sig, um, and also its mission and you know, your origin story. Like how did you discover the Milkin conference and like what brought you here today, some of your favorite moments. We got a lot to cover. I know that sounds like a lot.
Sounds like fun. Oh yeah. But, uh, we’re gonna start this episode the way that we start them all. We have something on the show, Ken, that we call our Mission Matters minute. And so, Ken, we at Mission Matters, we amplify stories for entrepreneurs, executives, and experts. That’s our mission. Ken, what mission matters to you?
Well, the mission we’re on is to improve, uh, the outcomes for a surgery called cardiac ablation. Somebody that has a rapid heart rhythm or AFib, where your heart is. It’s, uh, something that has to get fixed and we’re on a mission to do it better and faster. Seems simple, but it’s really important. Wonderful.
And, uh, we’ll, we’ll definitely get more into that as well, but, uh, get us kicked off here. Um, h how did you discover the Milkin Conference and just the Milkin Institute in general? Well, that’s a good, uh, long story, but I’ll give you the shorter version. So my background, I actually started my career on Wall Street in New York City, uh, back in the day of Milin.
And I worked for a great firm called Seligman, which, uh, has notoriety as being one of the top technology investors in the United States. And, uh, Mike Milken and Drexel Burnham, uh, back in their heyday were. Providing financing for industries that really didn’t exist in the United States. So like the wireless industry, cable television, cable television programming, so many others.
And he would basically help these industries get started from scratch. And then we, at our organization, were investing large sums of money. Through the stock market, uh, to support these companies. So, uh, one of the companies, uh, that really rings, uh, such a great memory for me is Mirage Resorts. Mike Milken provided the original financing for Steve Wynn to build the Mirage, which really started the transformation of Las Vegas as we know it today.
Uh, back when I first started investing in that company, Milin was really the first one to take the risk on that transformation. So, uh, my, uh, origin is that, and then, uh, through one of our shareholders we’re a publicly traded company on the nasdaq. Um, they recommended that I, uh, meet, uh, Lorraine Burch, uh, who was going to accommodate me, uh, to attend the Milkin conference.
And it turned out that we knew so many people in common and had so much background that overlapped. Uh, she ended up joining our board of advisors. So she’s been a terrific Sherpa here at the Milton Conference. And this being our first year here, it’s really the most amazing environment I’ve seen in 33 years.
Yeah, that’s how, that’s how amazed I am. So I’ve learned, so this is my, my second time at the conference. Mm-hmm. And one of my big goals is really to educate our audience and really others out there about the milk and institute, the great work that’s taking place here. And I learned this term recently when doing the interview.
It was called Milk and Magic. It’s this idea that when you, you come here, you meet other people, other like-minded people. Mm-hmm. Other people that really wanna do. Good in the world. Mm-hmm. Um, what kind of advice, like there’s other corporate leaders out there right now that’ll be watching this, that are thinking about like, you know, their involvement, what they should be doing, like what kind of message would you give them in terms of like milking and maybe their participation?
I think, uh, the United States needs more companies with mission. Uh, that are trying to fix problems or solve issues, uh, we saw an opportunity to improve heart surgery. Yeah. Uh, we saw a big gap and we thought technology could be an answer. So we’re 14 years into our journey and the thing that I am just completely, uh, in awe of is, You call it milk and ma magic?
Mm-hmm. It’s the, uh, it’s a collaborative group of the most purpose-driven people that I, I, I know of. And it’s not that easy to get in here. Oh, you have to come in via invitation, which means somebody’s gotta evaluate that you have something worthy of contributions. So my advice is, uh, find a large problem.
Get a team, find some way to, uh, get the resources to build it up and then bring it forward. And if it’s important, believe it or not, this organization finds a way to invite you in. And, you know, in terms of US medical innovation is really one of the big pillars of what Milk and Institute believes in.
They have a number of branches. One of them is called Faster Cures. Uh, that’s a new book that he just published talking about how technology and innovation can push forward, uh, the medical, uh, industry and help deal with our aging population. So it’s just a privilege to be part of it. Um, and I don’t know of any other platform Yeah.
In the United States or frankly the world that is so well thought through and so comprehensive. It’s really been an amazing experience. That’s for sure. So speaking of, um, you know, taking your own advice mm-hmm. At some point you, uh, you, you made the decision to tackle and to handle a large problem.
Mm-hmm. Which is your, your current present day, like from Wall Street guy to that like mm-hmm. You gotta gimme a little of that. How did that happen? Nine 11. Uh, being a New Yorker and having that kind of disruption. Mm-hmm. Um, it really allowed me to take a look at what I was doing. I was investing money for others.
We were doing a good job of that, but I just took a pause after that event to think about. I. How am I gonna spend the rest of my career? I was 31 years old at the time, and luckily I was, uh, able to walk away. I had some resources and I, I took my time to figure out what I wanted to do. I had some very good mentors, uh, folks who had, uh, built some other medical technology companies, and I sort of went to school on how to do it.
And it took me, uh, roughly seven years courage to start. Uh, Biosys. We started in the. Of the last pandemic, pardon me? We started the depths of the last financial crisis. Mm-hmm. So 2009, uh, when General Electric was rumored to be going bankrupt. Yeah. Up came the company here in Los Angeles. So we’re in Santa Monica about a mile from the Milken Institute.
Yeah. Which is kind of great. So tell us a little bit more about, I, um, you mentioned some of the problems that you’re handling at the company. Mm-hmm. Like, maybe go a little bit further and tell us a little bit more about the directives and what you’re working on. So we innovated a technology that helps see, Uh, the body’s electrical signals in the heart better than anybody.
So I like to say we’re like the Google Maps Yeah. Of heart surgery. So we, uh, take information from inside your heart. We process it through our computer system and we provide, uh, our physicians, uh, Real-time decision making capabilities that are new to them, uh, but are in addition to what they’re already currently using, help them make more confident decisions.
Uh, the physicians are really our customers. We stand behind them to support them in, uh, you know, doing heart surgery, which is no easy thing for them to do. And, uh, it’s been an amazing journey working with many of these folks to innovate the technology. Uh, some of the big highlights for us was in 2017.
The Mayo Clinic, uh, invested in our company and they had, they had basically helped us along with many others like U C L A, Texas Cardiac Arrhythmia Institute and others, uh, build up the technology to the point where it was valuable to the industry. And we launched the product right before Covid hit.
Yeah, so we had a little bit of a gap to jump over in terms of how Covid affected all of us. But you know, I’m just happy that we’re all here at this event. Nobody’s wearing masks and it shows you how medical innovation works in this country. We’ve been able to defeat a pandemic, although there are a lot of battle scars, but heart surgery is very important.
AFib is a growing, uh, Issue for the United States. There’s roughly, I don’t know, depending on whose numbers you believe, seven, 8 million people that have of this disease, rapid heart rhythms, 33 and a half million people around the world. And in 10 years that number’s gonna more than double. Mm-hmm. So one thing that Milin does at this conference is shows the impact of disease on society.
Impact of disease on the economy, impact of disease on families, everything from obesity d to Alzheimer’s to cardiovascular problems. And there’s a group of like-minded people here that are looking to try to find ways to help, Hmm. Try to find ways to solve these problems because these are big issues.
And the, just the expense of treating Alzheimer’s, uh, the, uh, slide that Milken put up the other day just still resonates in my head as wow. That’s a big problem. Somebody better tackle that. We’re tackling arrhythmias. Mm-hmm. Which is, you know, the fourth leading disease in the, in the US and, uh, the world is aging.
So these problems are very real and technology’s really our best solution. So we, we think we have a very good platform that we’re rolling out now and, um, you know, being here at Milton is just a, a total value add for us. It is. Okay, so, so switch switching focus slightly for a moment. Um, one of your favorite moments at Milk in 2023.
I know we’re not done yet, and I’m putting you on the spot, but I know there’s so many speakers, but one of your favorite moments. I didn’t say the favorite one of them. So yesterday this really sticks out. Uh, we had the opportunity to meet with, uh, two of, uh, Mike Milk’s oldest friends in the healthcare world, Andy Von Eschenbach and, uh, Neil Cael.
Both are, you know, been with Milken from the beginning. And, uh, just hearing their stories about. How they, uh, uh, dealt with Michael and how he engaged them was really, uh, mind altering. Uh, Andy Van Eschenbach was the physician at MD Anderson who provided milk in his cancer treatment. Mm-hmm. And you know, he’s here however many years later.
Yeah. I think it’s 30 years he’s been fighting, uh, prostate cancer and what he’s done for that industry, uh, for the people who suffer with prostate cancer, that alone is enough to blow your mind. And that’s just one thing this guy has done. Um, and Neil Cassel is the founder of the Focused Ultrasound Foundation, which is a new.
If somebody’s watching this mm-hmm. And if they wanna learn more about Bio Sig mm-hmm. And, uh, kind of follow the progress and the journey of the company, um, what’s the best way for them to do that? Well, there are two things I would say. One is our website is Bio sig dot. Com and we trade on the NASDAQ under ticker symbol B S G M.
And, um, you know, we intend to be here for quite some time. I hope we can keep coming back to this event. Uh, but you know, what we’re doing is important work. It’s exciting for anybody who has atrial fibrillation. I encourage you to learn more on our website. Read, read about our, uh, progress, uh, listen to the physicians that speak on our behalf.
And, uh, if you have any questions, please reach out to us. Fantastic. And we’ll definitely for all the audience, we’ll definitely put all those links in the show notes so that you can go, just click on the link and check it out. And, uh, Ken just wanna say, Hey, really appreciate you making some time for us today.
I know you’re busy at the conference, over out there absorbing that milk and magic and uh, making, making a difference. So thank you so much coming on. Really appreciate it. Thank you.